Results 61 to 70 of about 11,499 (250)

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

Advanced NanoBiomed Research, Volume 6, Issue 4, April 2026.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari, Yunhui Min, Eun‐Ju Ko, Doyoung Kwon, Rehan Khan, Young‐Ok Son   +5 more
wiley   +1 more source

Green Spectrofluorimetric Technique for the Determination of Vildagliptin Through Quenching Lanthanide Luminescence in Pure, Pharmaceutical Dosage Form and Spiked Plasma [PDF]

, 2022
Dina Mohamed, Maha Abou El- Alamin, Safaa Tubar   +2 more
openalex   +1 more source

From Heterogeneity to Plasticity: Endothelial Dynamics in Lung Disease

Pulmonary Circulation, Volume 16, Issue 2, June 2026.
ABSTRACT Endothelial heterogeneity and plasticity play an important role in lung development, homeostasis, and pathology. In recent years, increasing evidence has demonstrated that endothelial dysfunction contributes to the progression of various lung diseases, such as ADRS, PF, PH, and lung developmental disorders.
Van Dung Nguyen, Bisheng Zhou
wiley   +1 more source

IDF21-0400 Cross-sectional ObservaTional Study to assess Effectiveness, Safety of VildaglIptin/ MetfOrmin In T2D Patients – ACTION [PDF]

, 2022
Kaushik Biswas, Ipsa Mishra, K. Kavathiya, K. Korukonda   +3 more
openalex   +1 more source

SGLT2 inhibitors and mortality in older adults with diabetic kidney disease: A target trial emulation study

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 3126-3136, April 2026.
Abstract Aims Randomized controlled trials on sodium‐glucose cotransporter 2 (SGLT2) inhibitors have yielded inconsistent findings regarding mortality benefits. It remains unclear whether, and in which subgroups, SGLT2 inhibitors confer survival benefits in older adults with diabetic kidney disease (DKD).
Tatsuhiko Azegami, Hidehiro Kaneko, Akira Okada, Yuta Suzuki, Toshiyuki Ko, Kazuki Aoyama, Takashin Nakayama, Yuya Kimura, Katsuhiko Fujiu, Norifumi Takeda, Hiroyuki Morita, Takashi Yokoo, Koichi Node, Masaomi Nangaku, Norihiko Takeda, Hideo Yasunaga, Kaori Hayashi   +16 more
wiley   +1 more source

Postprandial Hypotension—Methods for the Evaluation and Management

Geriatrics &Gerontology International, Volume 26, Issue 4, April 2026.
Postprandial hypotension (PPH) is highly prevalent in older patients; however, its diagnosis remains challenging due to the absence of a consensus guideline for diagnostic criteria. Lifestyle modification is the first‐line management, taking into account the pathophysiology underlying PPH and the coexisting conditions of orthostatic hypotension and ...
Joji Ishikawa, Ayumi Toba, Shutaro Futami, Kazumasa Harada   +3 more
wiley   +1 more source

Nanofibrous vildagliptin-eluting stents enhance re-endothelialization and reduce neointimal formation in diabetes: in vitro and in vivo

International Journal of Nanomedicine, 2019
Chen-Hung Lee,1 Ming-Jer Hsieh,1 Shang-Hung Chang,1 Kuo-Chun Hung,1 Chao-Jan Wang,2 Ming-Yi Hsu,2 Jyuhn-Huarng Juang,3 I-Chang Hsieh,1 Ming-Shien Wen,1 Shih-Jung Liu4,5 1Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial ...
Lee CH, Hsieh MJ, Chang SH, Hung KC, Wang CJ, Hsu MY, Juang JH, Hsieh IC, Wen MS, Liu SJ   +9 more
doaj  

The effect of concomitant DPPIVi use on glycaemic control and hypoglycaemia with insulin glargine 300 U/mL (Gla-300) versus insulin glargine 100 U/mL (Gla-100) in people with type 2 diabetes: A patient-level meta-analysis of EDITION 2 and 3 [PDF]

, 2018
Aims To evaluate the effect of concomitant dipeptidyl peptidase IV inhibitor (DPPIVi) use on efficacy and safety of insulin glargine 300 U/mL (Gla-300) versus glargine 100 U/mL (Gla-100) in people with type 2 diabetes on oral antihyperglycaemic drugs ...
Brito-Sanfiel, Miguel, Buzzetti, Raffaella, Chevalier, Soazig, Lavalle-Gonzalez, Fernando, Merino-Trigo, Ana, Pettus, Jeremy Hodson, Stella, Peter, Yale, Jean-François   +7 more
core   +4 more sources

Safety of anagliptin/metformin combination tablets evaluated by non‐inferiority between pre‐ and post‐serum lactic acid levels in Japanese patients with type 2 diabetes and moderate renal impairment (AMELIO STUDY)

Journal of Diabetes Investigation, Volume 17, Issue 4, Page 636-648, April 2026.
To investigate the safety of anagliptin/metformin combination tablets in Japanese patients of type 2 diabetes with moderate renal impairment. This study demonstrates that the fixed‐dose combination of anagliptin and metformin can be used safely in patients with type 2 diabetes complicated by moderate renal dysfunction.
Hiroshi Kajio, Ryotaro Bouchi, Mitsuhisa Komatsu, Masanori Yamazaki, Daisuke Takarabe, Masahide Okamoto, Takahisa Tanaka, Toru Kitazawa, Hisayuki Katsuyama, Yasumichi Mori, Mitsuhiko Noda   +10 more
wiley   +1 more source

Vildagliptin Reduces Stenosis of Injured Carotid Artery in Diabetic Mouse Through Inhibiting Vascular Smooth Muscle Cell Proliferation via ER Stress/NF-κB Pathway

Frontiers in Pharmacology, 2019
Dipeptidyl peptidase-4 (DPP-4) inhibitors are novel anti-hyperglycemic drugs for type 2 diabetes. It has been reported that DDP-4 inhibitor could exert pleiotropic effects on cardiovascular system.
Yuqin Ji, Yingbin Ge, Xinyu Xu, Sen Ye, Yuansheng Fan, Jing Zhang, Lianlian Mei, Xiaofeng Zhang, Lianghong Ying, Tao Yang, Chunjian Li   +10 more
doaj   +1 more source